A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Diclofenac Potassium Tablets (Diclofenac Potassium)

First FDA approval2022-05-12
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.101/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$2.51
Across all dosage forms in distribution.
Highest NADAC
$3.72
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema8 entries indexed · 4 visible
What is Diclofenac Potassium Tablets used for?

Diclofenac Potassium Tablets is a this drug class medication tracked in Medicare Part D.

Is there a generic for Diclofenac Potassium Tablets?

No. Diclofenac Potassium Tablets is brand-only with no generic equivalents currently in market.

How much does my plan pay for Diclofenac Potassium Tablets?

Across 329 Part D plans, Diclofenac Potassium Tablets averages $2.51/unit (NADAC). Lowest available: $0.101/unit. Highest in distribution: $3.72/unit.

Is Diclofenac Potassium Tablets on the FDA shortage list?

No. Diclofenac Potassium Tablets is not currently on the FDA Drug Shortage Database.

4 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.